New shot shows promise for tough eczema in Mid-Stage trial
Disease control
Ongoing
This study tests whether an experimental drug, TRIV-509, can help adults with moderate to severe atopic dermatitis (eczema). About 95 participants will receive either TRIV-509 or a placebo for 16 weeks, then switch to the other treatment. The goal is to see if the drug improves s…
Phase: PHASE2 • Sponsor: Triveni Bio • Aim: Disease control
Last updated May 01, 2026 15:59 UTC